118159-53-8

Basic information

• Product Name: Phenol, 4-aMino-2,6-dichloro-5-fluoro-
• Synonyms: Phenol, 4-aMino-2,6-dichloro-5-fluoro-;4-AMino-2,6-dichloro-3-fluorophenol
• CAS NO: 118159-53-8
• Molecular Formula: C6H4Cl2FNO
• Molecular Weight: 196.0064632
• Mol File: 118159-53-8.mol

Chemical Properties

• Boiling Point: 297.7±40.0 °C(Predicted)
• Appearance: /
• Density: 1.657±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 6.31±0.28(Predicted)
• CAS DataBase Reference: Phenol, 4-aMino-2,6-dichloro-5-fluoro-(CAS DataBase Reference)
• NIST Chemistry Reference: Phenol, 4-aMino-2,6-dichloro-5-fluoro-(118159-53-8)
• EPA Substance Registry System: Phenol, 4-aMino-2,6-dichloro-5-fluoro-(118159-53-8)

Safety Data

• Hazardous Substances Data: 118159-53-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Phenol, 4-amino-2,6-dichloro-5-fluorois used as a therapeutic agent for the treatment of osteoporosis in postmenopausal women. It serves to increase bone density by mimicking the effects of estrogen, thereby reducing the risk of fractures.
Used in Oncology:
Phenol, 4-amino-2,6-dichloro-5-fluorois used as a preventive measure to lower the risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk for breast cancer. Its selective estrogen receptor modulating properties contribute to this protective effect.

Upstream product

• 394-41-2 3-fluoro-4-nitrophenol 
• 83121-15-7 3,5-dichloro-2,4-difluoro-aniline 

Relevant articles and documents

Metabolism of the insecticide teflubenzuron in rats

1. The metabolic fate of the insecticide teflubenzuron, orally dosed to the male Wistar rat, was investigated. Particular attention was paid to the metabolic fate of the benzoyl and aniline moiety after hydrolysis of the urea bridge. 2. The 0-48-h urinary and faecal metabolic patterns and recoveries showed that for a dose range of 4-53 μmol (1.5-20 mg) teflubenzuron, 90% of the dose was excreted in the faeces mainly in unmodified form, approximately 4.6% was absorbed from the lumen and excreted in the urine, and 5.4% was retained in the body. Metabolites excreted in the urine could be identified as benzoate and aniline derivatives originating from the two aromatic rings of teflubenzuron liberated from the parent molecule by hydrolysis of the urea bridge. 3. The amount of urinary benzoate-type metabolites was about eight times the amount of aniline-type metabolites, indicating significant differences in efficiency of urinary excretion of the benzoate moiety as compared with the aniline ring. 4. To investigate further the possible reason underlying this difference in urinary excretion efficiency between the two aromatic derivatives formed from teflubenzuron, dose-recovery studies of these aniline- and benzoate-type metabolites were performed. These studies confirmed the discrepancy observed between the urinary recovery of the benzoyl and the aniline moiety of teflubenzuron. 5. Additional results of the present study indicate that the above discrepancy can be explained by the fact that the benzoate derivative is excreted mainly in its unmetabolized form, whereas the aniline derivative needs additional phase I and II modifications before it can be excreted from the body, the former being a relatively slow reaction. Furthermore, conversion of the halogenated aniline derivative in phase I metabolism might result in a reactive benzoquinone-type or N-oxidized primary metabolite, which can be retained in the body due to reaction with cellular macromolecules.

THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF

Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with thyroid hormone receptor activity. The methods and compositions disclosed herein include the use of at least one thyroid hormone receptor agonist.